Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612558 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
A Phase 2 study of Warm Antibody Autoimmune Hemolytic Anemia, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 20
- Study locations
NCT02612558 is a Phase 2 study of Warm Antibody Autoimmune Hemolytic Anemia that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 26 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02612558, a Phase 2 study of Warm Antibody Autoimmune Hemolytic Anemia, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
Conditions Studied
Interventions
- DRUG Fostamatinib 150 mg bid
Study Locations (20)
California
- UC San Diego Moores Cancer Center - La Jolla
- Loma Linda University Cancer Center - Loma Linda
- LAC/USC Health Center - Los Angeles
- University of California at San Francisco - San Francisco
- The Oncology Institute of Hope and Innovation - Whittier
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Oncology Associates, PC - Tucson
Maryland
- Johns Hopkins University School Of Medicine - Baltimore
- Rcca Md Llc - Bethesda
New York
- Roswell Park Cancer Institute - Buffalo
- Montefiore Medical Center - The Bronx
North Carolina
- Brody School of Medicine at East Carolina University - Greenville
- W.G. "Bill" Hefner VA Medical Center - Salisbury
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Florida
- Mid-Florida Hematology & Oncology Centers, P.A. - Orange City
Kentucky
- Montgomery Cancer Center - Mount Sterling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02612558
The ClinicalTrials.gov registry entry for NCT02612558 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Warm Antibody Autoimmune Hemolytic Anemia appearing as the primary indexed condition, and to 1 intervention - of which Fostamatinib 150 mg bid is the first listed.
NCT02612558 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, Maryland.
Frequently Asked Questions
What is clinical trial NCT02612558 about?
NCT02612558 is a clinical study titled "A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)". The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
What is the current status of trial NCT02612558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2016-07. Estimated completion is 2019-12.
What conditions does trial NCT02612558 study?
This clinical trial studies the following conditions: Warm Antibody Autoimmune Hemolytic Anemia.
What interventions are being tested in trial NCT02612558?
The interventions under investigation include: Fostamatinib 150 mg bid (DRUG).
Who is sponsoring clinical trial NCT02612558?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02612558 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Warm Antibody Autoimmune Hemolytic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.